Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

KRX/001060 stock hub

KRX/001060 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KRX/001060is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

695.4B

Korea Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

KRX/001060

In the news

Latest news · KRX/001060

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 9.8P50 17.1P75 31.9

Trailing P/E12

P25 12P50 23.1P75 39.5

ROE17.6

P25 -17.1P50 0.7P75 8.5

ROIC17.3

P25 -9P50 1.3P75 6.8

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KRX/001060 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

236

Groups with data

Currency

KRW

Showing 236 of 236 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	South Korea
Country code	KR
Employees	1,068
Enterprise value	KRW 688.7B
Exchange	Korea Stock Exchange
Financial currency	KRW
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	KR7001060003
Last refreshed	2026-05-10
Market cap	KRW 695.4B
Price	KRW 30,450
Price currency	KRW
Rev Per Employee	725,934,511.15x
Sector	Healthcare
Sic	2834
Symbol	krx/001060
Website	https://www.jw-pharma.co.kr

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	8.85%
EV Earnings	11.2x
EV/EBIT	7.64x
EV/EBITDA	6.32x
EV/FCF	8.14x
EV/Sales	0.89x
FCF yield	12.17%
P/B ratio	1.88x
P/E ratio	12.02x
P/S ratio	0.9x
PE Ratio3 Y	14.52x
PE Ratio5 Y	25.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.33%
EBITDA Margin	13.75%
FCF margin	10.92%
Gross margin	46.35%
Gross Profit	KRW 359.3B
Gross Profit Growth	11.07%
Gross Profit Growth Q	8.27%
Gross Profit Growth3 Y	7.66%
Gross Profit Growth5 Y	15.14%
Net Income	KRW 61.5B
Net Income Growth	-5.43%
Net Income Growth Q	-7.69%
Net Income Growth Years	0%
Net Income Growth3 Y	24.48%
Pretax Margin	11.46%
Profit Margin	7.93%
Profit Per Employee	KRW 57.6M
Profitable Years	4
ROA	9.08
Roa5y	7.22
ROCE	22.18
ROE	17.6
Roe5y	13.76
ROIC	17.31
Roic5y	13.45

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	0.87%
Cagr15y	8.55%
Cagr1y	41.72%
Cagr20y	6.65%
Cagr3y	10.54%
Cagr5y	4.77%
Div CAGR10	18.44%
Div CAGR3	17.57%
Div CAGR5	16.01%
EPS Growth	-4.16
EPS Growth Q	-2.29
EPS Growth Years	0
EPS Growth3 Y	22.66
FCF Growth	19.06%
FCF Growth Q	41.24%
FCF Growth3 Y	21.79%
FCF Growth5 Y	10.8%
OCF Growth	21.42%
OCF Growth Q	45.38%
OCF Growth3 Y	19.31%
OCF Growth5 Y	8.86%
Revenue Growth	7.77x
Revenue Growth Q	5.9x
Revenue Growth Quarters	4x
Revenue Growth Years	1x
Revenue Growth3 Y	4.25x
Revenue Growth5 Y	7.21x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	KRW 1.28
Assets	KRW 605.3B
Cash	KRW 61.3B
Current Assets	KRW 296.5B
Current Liabilities	KRW 209.2B
Debt	KRW 54.6B
Debt EBITDA	KRW 0.51
Debt Equity	KRW 0.15
Debt FCF	KRW 0.65
Equity	KRW 369.4B
Interest Coverage	19.86
Liabilities	KRW 235.9B
Long Term Assets	KRW 308.8B
Long Term Liabilities	KRW 26.7B
Net Cash	KRW 6.7B
Net Cash By Market Cap	KRW 0.96
Net Debt EBITDA	KRW -0.06
Net Debt Equity	KRW -0.02
Net Debt FCF	KRW -0.08
Tangible Book Value	KRW 356.5B
Tangible Book Value Per Share	KRW 12,734
WACC	9.75

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.42
Inventory Turnover	3.75
Net Working Capital	KRW 62.2B
Quick ratio	0.86
Working Capital	KRW 87.4B
Working Capital Turnover	KRW 8.37

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.32%
Dividend Growth	0%
Dividend Growth Years	9%
Dividend per share	KRW 450
Dividend Years	1
Dividend Yield	1.48%
Ex Div Date	2026-03-31
Last Dividend	KRW 650
Payout Frequency	Annual
Payout Ratio	17.99%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	9.07%
1Y total return	41.68%
200-day SMA	26,788.8
3Y total return	35.07%
50-day SMA	31,383
50-day SMA vs 200-day SMA	50over200
5Y total return	26.26%
All Time High	82,903.3
All Time High Change	-63.27%
All Time High Date	2016-09-27
All Time Low	1,594.3
All Time Low Change	1,809.92%
All Time Low Date	2000-12-04
ATR	1,145.9
Beta	1.06
Beta1y	0.42
Beta2y	0.58
Ch YTD	19.41
High	30,700
High52	39,250
High52 Date	2026-02-23
High52ch	-22.42%
Low	30,200
Low52	20,700
Low52 Date	2025-10-13
Low52ch	47.1%
Ma50ch	-2.97%
Price vs 200-day SMA	13.67%
RSI	46.09
RSI Monthly	55.43
RSI Weekly	51.77
Sharpe ratio	0.99x
Sortino ratio	1.72
Total Return	2.8%
Tr YTD	21.96
Tr15y	242.4%
Tr1m	6.47%
Tr1w	-0.81%
Tr3m	-7.03%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	KRW 87.9B
Operating Income Growth	6.22
Operating Income Growth Q	-51.53
Operating Income Growth3 Y	13.26
Operating margin	11.33

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	12,897,150%
Net Borrowing	-39,167,438,360
Shares Insiders	0.81%
Shares Institutions	8.28%
Shares Out	22,886,936
Shares Qo Q	22.32%
Shares Yo Y	-1.32%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	KRW 84.6B
Average Volume	75,140.9x
Bv Per Share	13,194.2
CAPEX	KRW -11.8B
Ch10y	-3.52
Ch15y	190.5
Ch1m	6.47
Ch1w	-0.81
Ch1y	38.72
Ch20y	181.1
Ch3m	-8.97
Ch3y	28.34
Ch5y	16.02
Ch6m	25.31
Change	-0.16%
Change From Open	-0.16
Close	30,500
Days Gap	0
Depreciation Amortization	18,747,598,000
Dollar Volume	1,041,603,150
Earnings Date	2026-05-14
EBIT	KRW 87.9B
EBITDA	KRW 106.6B
EPS	KRW 2,534
F Score	6
FCF	KRW 84.6B
FCF EV Yield	12.29x
FCF Per Share	KRW 3,698
Financing CF	-59,775,532,160
Fiscal Year End	December
Founded	1,945
Graham Number	27427.44899
Graham Upside	-9.93
Income Tax	KRW 27.3B
Investing CF	-7,198,190,580
Is Primary Listing	1
Last Earnings Date	2025-11-14
Last Report Date	2025-12-31
Last Split Date	2023-12-27
Last Split Type	Forward
Lynch Fair Value	KRW 62,027
Lynch Upside	103.7
Ma150	28,274.3
Ma150ch	7.69%
Ma20	31,210
Ma20ch	-2.44%
Net CF	28,802,997,920
Next Earnings Date	2026-05-14
Open	30,500
P FCF Ratio	8.22
P OCF Ratio	7.21
Payment Date	2026-04-24
Position In Range	50
Ppne	165,279,423,680
Price Date	2026-05-08
Price EBITDA	KRW 6.52
Ptbv Ratio	1.95
Relative Volume	0.46x
Revenue	775,298,057,910x
Tax By Revenue	3.52x
Tax Rate	30.76%
Tr20y	262.47%
Tr6m	27.98%
Volume	34,207
Z Score	3.79

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

KRX/001060 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.5%

$450 annual per share

Payout ratio

+18.0%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+16.0%

9 consecutive years of growth

Total shareholder yield

+2.8%

Next ex-dividend date: 2026-03-31

Performance

KRX/001060 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KRX/001060?

Insider, institutional, and short-interest positioning.

Institutional ownership

+8.3%

Share of float held by funds and institutions

Insider ownership

+0.8%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-1.3%

Negative means the company is buying back shares.

Technical

KRX/001060 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.1

Neutral momentum band

Price vs 200-day MA

+13.7%

50/200-day relationship not available

Beta (5Y)

1.06

Moves roughly with the market

Sharpe ratio

0.99

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KRX/001060

Hub-level FAQ points readers to the deeper analysis pages.

What is the current krx/001060 stock rating?

krx/001060 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full krx/001060 analysis?

The full report lives at /stocks/krx/001060/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for krx/001060?

The latest report frames krx/001060 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the krx/001060 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.